Kazia Therapeutics Ltd (KZA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kazia Therapeutics Ltd (KZA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12402
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology platforms, phosphoinositide 3-kinase (PI3K) inhibitors, anti-tropomyosins (ATM) and super-benzopyrans (SBP). ATM drugs that target the cancer cell cytoskeleton are being developed for the treatment of melanoma, prostate cancer and neuroblastoma. SBP drugs that target cancer stem cells are being developed for the treatment of ovarian cancer and glioblastoma. The PI3K inhibitor functions by inhibiting an important signaling pathway which is critical to the development of certain kinds of tumors. The company’s product pipeline includes PI3K GDC-0084; Cantrixil (TRX-E-002-1). Kazia is headquartered in New South Wales, Australia.

Kazia Therapeutics Ltd (KZA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Novogen Acquires Anti-Tropomyosins Drug Technology From Genscreen 12
Partnerships 14
Kazia Therapeutics Enters into Partnership with Dana-Farber Cancer Institute 14
Kazia Therapeutics Enters into Co-Development Agreement with St Jude Children’s Research Hospital 15
Noxopharm Enters into Agreement with Kazia Therapeutics 16
Novogen Enters into Contract Research Agreement with Novotech 17
Novogen to Enter into Co-Development Agreement with Feinstein Institute for Medical Research for Brain Cancer 18
Novogen Enters into Agreement with Genea Biocells 19
Novogen Forms Joint Venture With Yale University 20
Novogen Enters Into Agreement With The Ingham Institute For Applied Medical Research 22
Licensing Agreements 23
Heaton-Brown Life Sciences Enters into Licensing Agreement with Novogen 23
Novogen Enters into Licensing Agreement with Genentech for GDC-0084 24
Equity Offering 25
Kazia Therapeutics Raises USD0.6 Million in Share Purchase Plan 25
Kazia Therapeutics Raises USD2.4 Million in Private Placement of Shares 26
Kazia Therapeutics Files Registration Statement for Public Offering of American Depositary Shares and Warrants for up to USD100 Million 28
Novogen Raises USD13 Million in Rights Offering of Shares 29
Novogen to Raise USD0.51 Million in Private Placement of Shares 31
Novogen Raises USD12 Million in Private Placement of Shares 32
Novogen to Raise Additional USD1.4 million in Private Placement of Shares 33
Novogen Raises USD1.6 Million in Private Placement of Shares 35
Novogen Completes Second Tranche Of Private Placement Of Shares For US$0.14 Million 36
Novogen Completes Rights Offering Of Shares For US$0.8 Million 37
Novogen Completes Private Placement Of Shares For US$2 Million 38
Debt Offering 39
Novogen Completes Third Tranche of Private Placement Of Private Placement Of Note For US$3.7 Million 39
Asset Transactions 40
TroBio Therapeutics Acquires ATM Program from Kazia Therapeutics 40
TR Therapeutics Completes Acquisition Of Glucan Technology Assets From Novogen 41
Acquisition 42
Novogen Acquires Glioblast for USD1.6 Million 42
Novogen Completes Acquisition Of Triaxial Pharma For US$2 Million 43
Kazia Therapeutics Ltd – Key Competitors 44
Kazia Therapeutics Ltd – Key Employees 45
Kazia Therapeutics Ltd – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Financial Announcements 47
Aug 29, 2017: Novogen Annual Report And Full-year Financial Results 47
Corporate Communications 49
Jun 08, 2017: Novogen Streamlines Board and Costs 49
Mar 10, 2017: Novogen Announces Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure 50
Mar 10, 2017: Novogen: Transformation To A Clinical Stage Organisation Leads To Changes In Management Structure 51
Product News 52
05/07/2018: Emerging oncology researcher says women lose out as ovarian cancer treatments lag 52
Clinical Trials 53
Sep 13, 2018: Australian clinical trial of ovarian cancer therapy Cantrixil pivotal for cancer stem cell research 53
Jun 19, 2018: Kazia Releases Preliminary Cantrixil Phase I Data 54
Aug 07, 2017: Progress Update on Cantrixil (TRXE-002-1) Development 55
Other Significant Developments 57
Feb 19, 2018: Kazia Change Of Registered Office And Business Address 57
Aug 14, 2017: Novogen: Board Review Of Business Operations And Governance 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kazia Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Novogen Acquires Anti-Tropomyosins Drug Technology From Genscreen 12
Kazia Therapeutics Enters into Partnership with Dana-Farber Cancer Institute 14
Kazia Therapeutics Enters into Co-Development Agreement with St Jude Children’s Research Hospital 15
Noxopharm Enters into Agreement with Kazia Therapeutics 16
Novogen Enters into Contract Research Agreement with Novotech 17
Novogen to Enter into Co-Development Agreement with Feinstein Institute for Medical Research for Brain Cancer 18
Novogen Enters into Agreement with Genea Biocells 19
Novogen Forms Joint Venture With Yale University 20
Novogen Enters Into Agreement With The Ingham Institute For Applied Medical Research 22
Heaton-Brown Life Sciences Enters into Licensing Agreement with Novogen 23
Novogen Enters into Licensing Agreement with Genentech for GDC-0084 24
Kazia Therapeutics Raises USD0.6 Million in Share Purchase Plan 25
Kazia Therapeutics Raises USD2.4 Million in Private Placement of Shares 26
Kazia Therapeutics Files Registration Statement for Public Offering of American Depositary Shares and Warrants for up to USD100 Million 28
Novogen Raises USD13 Million in Rights Offering of Shares 29
Novogen to Raise USD0.51 Million in Private Placement of Shares 31
Novogen Raises USD12 Million in Private Placement of Shares 32
Novogen to Raise Additional USD1.4 million in Private Placement of Shares 33
Novogen Raises USD1.6 Million in Private Placement of Shares 35
Novogen Completes Second Tranche Of Private Placement Of Shares For US$0.14 Million 36
Novogen Completes Rights Offering Of Shares For US$0.8 Million 37
Novogen Completes Private Placement Of Shares For US$2 Million 38
Novogen Completes Third Tranche of Private Placement Of Private Placement Of Note For US$3.7 Million 39
TroBio Therapeutics Acquires ATM Program from Kazia Therapeutics 40
TR Therapeutics Completes Acquisition Of Glucan Technology Assets From Novogen 41
Novogen Acquires Glioblast for USD1.6 Million 42
Novogen Completes Acquisition Of Triaxial Pharma For US$2 Million 43
Kazia Therapeutics Ltd, Key Competitors 44
Kazia Therapeutics Ltd, Key Employees 45
Kazia Therapeutics Ltd, Subsidiaries 46

List of Figures
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Kazia Therapeutics Ltd (KZA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Emsland Group:企業の戦略・SWOT・財務情報
    Emsland Group - Strategy, SWOT and Corporate Finance Report Summary Emsland Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • S Chand And Company Limited (SCHAND):企業の財務・戦略的SWOT分析
    S Chand And Company Limited (SCHAND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • The Royal Bank of Scotland Group Plc:企業のM&A・事業提携・投資動向
    The Royal Bank of Scotland Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Royal Bank of Scotland Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports …
  • Immunicom Inc-医療機器分野:企業M&A・提携分析
    Summary Immunicom Inc (Immunicom) is a specialty biotechnology company with focus on the development of a blood filtering device for the treatment of cancer and autoimmune diseases. The company’s lead program, sTNFR Immunopheresis, is a non-drug based cancer therapy that uses a proprietary immunoads …
  • Amicus Therapeutics Inc (FOLD):企業の財務・戦略的SWOT分析
    Amicus Therapeutics Inc (FOLD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Quadra – Power Generation (TGKD):電力:M&Aディール及び事業提携情報
    Summary Quadra - Power Generation (Quadra) is an electric utility. It generates electricity and sells that on wholesale basis and in capacity market; and produces, transports, and sells thermal energy on retail market. The company has production facilities in Lipetsk, Voronezh, Tambov, Kursk, Belgor …
  • BioTex Inc:企業の製品パイプライン分析
    Summary BioTex Inc (BioTex) operates as a medical device company that designs, develops, manufactures and distributes electro-mechanical, optical and software based devices. The company offers sterile and non-sterile disposable products for surgical, non-surgical and interventional procedures in dia …
  • Sienna Biopharmaceuticals Inc (SNNA):医療機器:M&Aディール及び事業提携情報
    Summary Sienna Biopharmaceuticals Inc (Sienna Biopharmaceuticals) is a clinical-stage biopharmaceutical company that develops and commercializes topical products in medical dermatology and aesthetics. Through its topical photoparticle therapy platform, the company advanced its product SNA-001, into …
  • Naspers Limited (NPN):企業の財務・戦略的SWOT分析
    Naspers Limited (NPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • A.P. Moller – Maersk AS (MAERSK B)-石油・ガス分野:企業M&A・提携分析
    Summary A.P. Moller - Maersk A/S (APM) is a business conglomerate that carries out operations in global trade, shipping and energy. It operates through a network of tankers, supply ships, container vessels, car carriers, drilling rigs and special vessels. The company also carries out container termi …
  • Steward Health Care System LLC:企業の戦略的SWOT分析
    Steward Health Care System LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Cohu Inc (COHU):企業の財務・戦略的SWOT分析
    Cohu Inc (COHU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • J.W. Ostendorf GmbH & Co KG:企業の戦略・SWOT・財務情報
    J.W. Ostendorf GmbH & Co KG - Strategy, SWOT and Corporate Finance Report Summary J.W. Ostendorf GmbH & Co KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • China Food Company PLC :企業の戦略・SWOT・財務情報
    China Food Company PLC - Strategy, SWOT and Corporate Finance Report Summary China Food Company PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Nacional Financiera S.N.C.:企業の戦略・SWOT・財務情報
    Nacional Financiera S.N.C. - Strategy, SWOT and Corporate Finance Report Summary Nacional Financiera S.N.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Marubeni Corp (8002):石油・ガス:M&Aディール及び事業提携情報
    Summary Marubeni Corp (Marubeni) is an integrated trading and investment business that operates through its domestic and overseas subsidiaries. It provides various products and commodities such as agri and marine products, chemicals, energy, metals and minerals, machinery, textiles, forest products …
  • Kia Motors Corporation (000270):企業の財務・戦略的SWOT分析
    Kia Motors Corporation (000270) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Piraeus Bank SA:企業のM&A・事業提携・投資動向
    Piraeus Bank SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Piraeus Bank SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Pioneer Corporation:企業の戦略・SWOT・財務分析
    Pioneer Corporation - Strategy, SWOT and Corporate Finance Report Summary Pioneer Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Iberdrola SA (IBE)-エネルギー分野:企業M&A・提携分析
    Summary Iberdrola, S.A. (Iberdrola) is an electric utility. The company generates, trades, transmits, distributes and markets electricity and gas. It operates hydroelectric, thermal and nuclear power plants in Spain and other countries. The company also involved in the production of electricity from …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆